The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...

Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports. Other equities analysts have also recently ...